Immuneed is proud to announce the start of a new cooperation with Lipum. Situated in Umeå, Sweden, Lipum is developing a new drug aimed at combatting chronic inflammatory conditions such as rheumatoid arthritis. Through a novel mode of action, the company’s monoclonal antibody targets a protein called bile salt-stimulated lipase (BSSL), which recruits inflammatory and immune cells to the site of an inflammation.
”We want to map and understand our antibody’s unique mode of action, which is what attracted us to Immuneed’s platform with intact, circulating blood,” says Dr. Pernilla Abrahamsson, Chief Operating Officer at Lipum. ”Immuneed’s method reflects what happens in the human body, especially as there are no anticoagulants involved. There is nothing to influence the bonds and receptors that we want to know more about.”
Behind Lipum’s project with Immuneed are extensive discussions and planning, which Abrahamsson sees as a cornerstone of successful cooperation. ”Drug development is both time-consuming and expensive, which makes it important for partners to understand one another,” she says. ”Creating a solid plan is vital, so that both sides are clear as to what should come out of the project.”
Throughout the process, Abrahamsson has found Immuneed a knowledgable sparring partner. ”There are so many different angles and possibilities for testing a new drug candidate,” she explains. ”To get real value from a project, you need to narrow things down at the start. That way you can understand the answers you get and build from there. Our dialog with Immuneed has been excellent, which has given us a better understanding of what we need to look at.”